Cathepsin D Deficiency Is Associated with a Human Neurodegenerative

Total Page:16

File Type:pdf, Size:1020Kb

Cathepsin D Deficiency Is Associated with a Human Neurodegenerative Cathepsin D Deficiency Is Associated with a Human Neurodegenerative Disorder Robert Steinfeld,1 Konstanze Reinhardt,1 Kathrin Schreiber,1 Merle Hillebrand,1 Ralph Kraetzner,2 Wolfgang Bru¨ck,3 Paul Saftig,4 and Jutta Ga¨rtner1 Departments of 1Pediatrics and Pediatric Neurology, 2Molecular Pharmacology, and 3Neuropathology, University of Go¨ttingen, Go¨ttingen, Germany; and 4Biochemical Institute, University of Kiel, Kiel, Germany Cathepsin D is a ubiquitously expressed lysosomal protease that is involved in proteolytic degradation, cell invasion, and apoptosis. In mice and sheep, cathepsin D deficiency is known to cause a fatal neurodegenerative disease. Here, we report a novel disorder in a child with early blindness and progressive psychomotor disability. Two missense mutations in the CTSD gene, F229I and W383C, were identified and were found to cause markedly reduced proteolytic activity and a diminished amount of cathepsin D in patient fibroblasts. Expression of cathepsin D mutants in cathepsin D5/5 mouse fibroblasts revealed disturbed posttranslational processing and intracellular tar- geting for W383C and diminished maximal enzyme velocity for F229I. The structural effects of cathepsin D mutants were estimated by computer modeling, which suggested larger structural alterations for W383C than for F229I. Our studies broaden the group of human neurodegenerative disorders and add new insight into the cellular functions of human cathepsin D. Cathespin D (CatD) belongs to the pepsin family of pro- age of an autofluorescent material, ceroid lipofuscin, is teases and is one of the most studied aspartic proteases. found in neurons.10 Inactivation of the Drosophila CatD It has been implicated in diverse biological processes. homologue causes age-dependent neurodegeneration CatD promotes invasion and proliferation of cancer and also progressive neuronal accumulation of autofluo- cells1 but is also involved in caspase-independent apo- rescent storage material.11 In sheep, a naturally occurring ptosis.2,3 Increased concentrations of CatD are found missense mutation in the active-site aspartate (D293N) during ischemic, inflammatory, and regenerative pro- of ovine Ctsd results in early neurodegeneration. Because cesses, such as coronary heart disease,4 inflammatory of the autofluorescent neuronal storage material, the dis- bowel disease,5 wound healing, and epidermal differ- ease was subsequently named “congenital ovine neuronal entiation.6 CatD is a major component of lysosomes and ceroid lipofuscinosis” (CONCL [MIM *116840]).12 functions as a highly active endopeptidase with an op- Recently, a second natural animal model of CatD in- timum pH between 3.0 and 5.0. CatD preferentially sufficiency was discovered in American bulldogs.13 Af- cleaves peptide bonds that are flanked by bulky hydro- fected dogs had 36% of the CatD-specific enzymatic phobic amino acids and is strongly inhibited by pepstatin activity found in control dogs, and they presented with p A (inhibition constantKi 1–4 nM). Human CatD is a milder phenotype than CatD-deficient mice and sheep. synthesized and translocated into the endoplasmic retic- Similar to these animal models, all currently known hu- ulum (ER) as an inactive precursor proenzyme (53 kDa), man neuronal ceroid lipofuscinosis (NCL) forms are processed into an enzymatically active, intermediate pro- characterized by developmental regression, visual loss, enzyme (48 kDa), and finally converted in the lysosomal and epilepsy in addition to the name-giving accumula- compartment into a noncovalently associated two-chain tion of autofluorescent lysosomal storage material. At form with an N-terminal 15-kDa light chain and a C- present, six different disease genes have been identified terminal 33-kDa heavy chain.7,8 for human NCL: CLN1, CLN2, CLN3, CLN5, CLN6, Targeted disruption of the Ctsd gene in mice leads to and CLN8.14,15 weight loss in the 3rd wk of life that is associated with We screened a group of 25 infants and children with progressive atrophy of the intestinal mucosa. Massive a nonidentified genetic cause of an NCL-like disorder intestinal necrosis and profound destruction of lympho- and found the first case of human CatD deficiency. We cytes in the spleen and thymus are found just before the determined the molecular mechanisms and functional mice die in a state of anorexia at age 4 wk.9 In addition, consequences of two missense mutations in the human CatD-deficient mice develop seizures and progressive ret- CTSD gene, and, in doing so, have extended our un- inal atrophy, which leads to blindness. Lysosomal stor- derstanding of the biological functions of human CatD. Received December 12, 2005; accepted for publication March 10, 2006; electronically published March 29, 2006. Address for correspondence and reprints: Dr. Robert Steinfeld, Pa¨diatrie II, Zentrum Kinderheilkunde und Jugendmedizin, Georg-August- Universita¨tGo¨ ttingen, Bereich Humanmedizin, Robert-Koch-Strasse 40, D-37075 Go¨ ttingen, Germany. E-mail: [email protected] Am. J. Hum. Genet. 2006;78:988–998. ᭧ 2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7806-0009$15.00 988 The American Journal of Human Genetics Volume 78 June 2006 www.ajhg.org Material and Methods was clearly reduced. Sequencing the coding regions of CTSD resulted in the identification of the missense mutations g.6517TrA and g.10267GrC, whereas no pathogenic base Material alterations were revealed in the CLN3, CLN5, CLN6, and Cell culture medium (Dulbecco’s modified Eagle medium CLN8 genes. [DMEM]), zeocin, hygromycin, Lipofectamin 2000, and Taq After a normal early psychomotor development, the patient DNA polymerase were purchased from Invitrogen. Oligonu- first showed neurodegenerative symptoms—in particular, cleotides were synthesized by MWG-Biotech. For amplification ataxia and visual disturbances—at early-school age. The ocular of genomic DNA fragments of CTSD, the primer combination fundus was found to show retinitis pigmentosa, and cranial hCDgDNA6960F (5-GTGTAAACCGAGCCCTGATGACTT-3) magnetic resonance imaging (MRI) scans revealed cerebral and and hCDgDNA7525R (5-CAGCAGCAGGGAGGGGGCAGC- cerebellar atrophy. In the course of disease, she developed pro- ACT-3) and the primer combination hCDgDNA10788F (5-GGG- gressive cognitive decline, loss of speech, retinal atrophy, and GAGCCCCAAGGCCACCACTA-3) and hCDgDNA11224R loss of motor functions. Now, at age 17 years, she is wheel- (5-CTCGGCGAAGCCCACCCTGTTGTT-3) were used. For chair bound and severely mentally retarded. Until now, there amplification of the CTSD cDNA fragments, the primer com- has been no evidence of hematological disease, immunodefi- bination hCDcDNA526F (5-CGTGAAGAATGGTACCTCG- ciency, intestinal abnormalities, or dystrophia. In fact, because TTTGA-3) and hCDcDNA1319R (5-CAGTGTAGTAGCG- of immobilization, the patient has become overweight during GCCGATGAAGAC-3) was used. [a-32P]dCTP, [35S]methio- the past few years. nine, and molecular-weight protein markers were obtained from Amersham Biosciences. Restriction enzymes were sup- Expression of Wild-Type CatD and Mutants in CatDϪ/Ϫ plied by New England BioLabs. Goat anti-human CatD an- Mouse Fibroblasts and Flp-In 3T3 Cells tibody and rabbit anti-mouse CatD antibody were a generous gift from Professor Kurt von Figura (University of Go¨ ttingen). CTSD cDNA was received from the IMAGE consortium Rat anti-mouse lysosomal-associated membrane protein 1 (RZPD clone ID IRAUp969A1048D6) and was cloned into (LAMP-1) antibody was acquired from the Developmental the expression vectors pcDNA3.1/Zeo and pEF5/FRT/V5-D- Studies Hybridoma Bank (University of Iowa, Iowa City). TOPO (Invitrogen). Site-directed mutagenesis was performed Biotin SP–conjugated donkey anti-goat antibody, peroxidase- using a QuickChange site-directed mutagenesis kit (Strata- conjugated donkey anti-goat antibody, and peroxidase-con- gene), in accordance with the supplier’s protocol. All final con- jugated streptavidin were purchased from Jackson Immuno- structs were verified by semiautomated sequencing. Ϫ Ϫ Research Lab. For western blotting, peroxidase staining was CatD / mouse fibroblasts and Flp-In 3T3 cells were seeded done with tetramethyl benzidine (TMB) substrate (Seramun). on 35-mm plates at a density of2 # 105 cells/well in DMEM Alexa Fluor 488 donkey anti-goat antibody and Alexa Fluor supplemented with fetal calf serum (FCS) at 37ЊC and 5% 546 goat anti-mouse and goat anti-rat antibodies were ob- CO2. After 24 h of culturing, the cells were transfected with tained from Molecular Probes. The BigDye terminator kit was 2 mg of plasmid and 5 ml of Lipofectamin 2000 in 0.5 ml of used for semiautomated sequencing, in accordance with the Opti-MEM. The medium was replaced with DMEM supple- recommendations of the manufacturer (Perkin Elmer Applied mented with FCS after 6 h of incubation. Selection with zeocin Biosystems). RNA was isolated from patient fibroblasts with or hygromycin was started 48 h after transfection, and stable the RNeasy kit as described by the manufacturer (Qiagen). clones were achieved after 14 d of selection. Cellular homog- Total RNA was fractionated by agarose-formaldehyde gel elec- enates from individual clones were assayed for CatD activity trophoresis, the gel was blotted onto a Hybond-XL membrane by use of the substrate MOCAc-GKPIIFFRLK(Dnp)-R-NH2, (Amersham Biosciences), and the northern blot was hybridized as described elsewhere.16 Alternatively, cell lysates were ana- in accordance with standard procedures by use of the Nick lyzed by western blotting
Recommended publications
  • Membrane Proteins • Cofactors – Plimstex • Membranes • Dna • Small Molecules/Gas • Large Complexes
    Structural mass spectrometry hydrogen/deuterium exchange Petr Man Structural Biology and Cell Signalling Institute of Microbiology, Czech Academy of Sciences Structural biology methods Low-resolution methods High-resolution methods Rigid SAXS IR Raman CD ITC MST Cryo-EM AUC SPR MS X-ray crystallography Chemical cross-linking H/D exchange Native ESI + ion mobility Oxidative labelling Small Large NMR Dynamic Structural biology approaches Simple MS, quantitative MS Cross-linking, top-down, native MS+dissociation native MS+ion mobility Cross-linking Structural MS What can we get using mass spectrometry IM – ion mobility CXL – chemical cross-linking AP – afinity purification OFP – oxidative footprinting HDX – hydrogen/deuterium exchange ISOTOPE EXCHANGE IN PROTEINS 1H 2H 3H occurence [%] 99.988 0.0115 trace 5 …Kaj Ulrik Linderstrøm-Lang „Cartesian diver“ Proteins are migrating in tubes with density gradient until they stop at the point where the densities are equal 1H 2H 3H % 99.9885 0.0115 trace density [g/cm3] 1.000 1.106 1.215 Methods of detection IR: β-: NMR: 1 n = 1.6749 × 10-27 kg MS: 1H 2H 3H výskyt% [%] 99.9885 0.0115 trace hustotadensity vody [g/cm [g/cm3] 3] 1.000 1.106 1.215 jadernýspinspin ½+ 1+ ½+ mass [u] 1.00783 2.01410 3.01605 Factors affecting H/D exchange hydrogen bonding solvent accessibility Factors affecting H/D exchange Side chains (acidity, steric shielding) Bai et al.: Proteins (1993) Glasoe, Long: J. Phys. Chem. (1960) Factors affecting H/D exchange – side chain effects Inductive effect – electron density is Downward shift due to withdrawn from peptide steric hindrance effect of bond (S, O).
    [Show full text]
  • Progress in the Field of Aspartic Proteinases in Cheese Manufacturing
    Progress in the field of aspartic proteinases in cheese manufacturing: structures, functions, catalytic mechanism, inhibition, and engineering Sirma Yegin, Peter Dekker To cite this version: Sirma Yegin, Peter Dekker. Progress in the field of aspartic proteinases in cheese manufacturing: structures, functions, catalytic mechanism, inhibition, and engineering. Dairy Science & Technology, EDP sciences/Springer, 2013, 93 (6), pp.565-594. 10.1007/s13594-013-0137-2. hal-01201447 HAL Id: hal-01201447 https://hal.archives-ouvertes.fr/hal-01201447 Submitted on 17 Sep 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Dairy Sci. & Technol. (2013) 93:565–594 DOI 10.1007/s13594-013-0137-2 REVIEW PAPER Progress in the field of aspartic proteinases in cheese manufacturing: structures, functions, catalytic mechanism, inhibition, and engineering Sirma Yegin & Peter Dekker Received: 25 February 2013 /Revised: 16 May 2013 /Accepted: 21 May 2013 / Published online: 27 June 2013 # INRA and Springer-Verlag France 2013 Abstract Aspartic proteinases are an important class of proteinases which are widely used as milk-coagulating agents in industrial cheese production. They are available from a wide range of sources including mammals, plants, and microorganisms.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Protease Inhibition—An Established Strategy to Combat Infectious Diseases
    International Journal of Molecular Sciences Review Protease Inhibition—An Established Strategy to Combat Infectious Diseases Daniel Sojka 1,* , Pavla Šnebergerová 1,2 and Luïse Robbertse 1 1 Biology Centre, Institute of Parasitology, Academy of Sciences of the Czech Republic, Branišovská 1160/31, CZ-37005 Ceskˇ é Budˇejovice,Czech Republic; [email protected] (P.Š.); [email protected] (L.R.) 2 Faculty of Science, University of South Bohemia in Ceskˇ é Budˇejovice,Branišovská 1760c, CZ-37005 Ceskˇ é Budˇejovice,Czech Republic * Correspondence: [email protected] Abstract: Therapeutic agents with novel mechanisms of action are urgently needed to counter the emergence of drug-resistant infections. Several decades of research into proteases of disease agents have revealed enzymes well suited for target-based drug development. Among them are the three recently validated proteolytic targets: proteasomes of the malarial parasite Plasmodium falciparum, aspartyl proteases of P. falciparum (plasmepsins) and the Sars-CoV-2 viral proteases. Despite some unfulfilled expectations over previous decades, the three reviewed targets clearly demonstrate that selective protease inhibitors provide effective therapeutic solutions for the two most impacting infectious diseases nowadays—malaria and COVID-19. Keywords: protease; parasites; inhibition; therapy; infectious diseases Citation: Sojka, D.; Šnebergerová, P.; Robbertse, L. Protease Inhibition—An 1. Introduction Established Strategy to Combat Infectious diseases, along with starvation, limited water resources and the lack of Infectious Diseases. Int. J. Mol. Sci. shelter, are among the main factors threatening the health and prosperity of the world’s 2021, 22, 5762. https://doi.org/ growing human population. Significant proportions of infectious diseases are caused by 10.3390/ijms22115762 parasites [1], the most common human infections being toxoplasmosis, ascariasis, ancy- lostomiasis and trichomoniasis.
    [Show full text]
  • Review Article the Role of Microbial Aspartic Protease Enzyme in Food and Beverage Industries
    Hindawi Journal of Food Quality Volume 2018, Article ID 7957269, 15 pages https://doi.org/10.1155/2018/7957269 Review Article The Role of Microbial Aspartic Protease Enzyme in Food and Beverage Industries Jermen Mamo and Fassil Assefa Microbial, Cellular and Molecular Biology Department, College of Natural Science, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia Correspondence should be addressed to Jermen Mamo; [email protected] Received 3 April 2018; Revised 16 May 2018; Accepted 29 May 2018; Published 3 July 2018 Academic Editor: Antimo Di Maro Copyright © 2018 Jermen Mamo and Fassil Assefa. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Proteases represent one of the three largest groups of industrial enzymes and account for about 60% of the total global enzymes sale. According to the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology, proteases are classied in enzymes of class 3, the hydrolases, and the subclass 3.4, the peptide hydrolases or peptidase. Proteases are generally grouped into two main classes based on their site of action, that is, exopeptidases and endopeptidases. Protease has also been grouped into four classes based on their catalytic action: aspartic, cysteine, metallo, and serine proteases. However, lately, three new systems have been dened: the threonine-based proteasome system, the glutamate-glutamine system of eqolisin, and the serine-glutamate-aspartate system of sedolisin. Aspartic proteases (EC 3.4.23) are peptidases that display various activities and specicities.
    [Show full text]
  • Data-Mining Approaches Reveal Hidden Families of Proteases in The
    Downloaded from genome.cshlp.org on October 5, 2021 - Published by Cold Spring Harbor Laboratory Press Letter Data-Mining Approaches Reveal Hidden Families of Proteases in the Genome of Malaria Parasite Yimin Wu,1,4 Xiangyun Wang,2 Xia Liu,1 and Yufeng Wang3,5 1Department of Protistology, American Type Culture Collection, Manassas, Virginia 20110, USA; 2EST Informatics, Astrazeneca Pharmaceuticals, Wilmington, Delaware 19810, USA; 3Department of Bioinformatics, American Type Culture Collection, Manassas, Virginia 20110, USA The search for novel antimalarial drug targets is urgent due to the growing resistance of Plasmodium falciparum parasites to available drugs. Proteases are attractive antimalarial targets because of their indispensable roles in parasite infection and development,especially in the processes of host e rythrocyte rupture/invasion and hemoglobin degradation. However,to date,only a small number of protease s have been identified and characterized in Plasmodium species. Using an extensive sequence similarity search,we have identifi ed 92 putative proteases in the P. falciparum genome. A set of putative proteases including calpain,metacaspase,and s ignal peptidase I have been implicated to be central mediators for essential parasitic activity and distantly related to the vertebrate host. Moreover,of the 92,at least 88 have been demonstrate d to code for gene products at the transcriptional levels,based upon the microarray and RT-PCR results,an d the publicly available microarray and proteomics data. The present study represents an initial effort to identify a set of expressed,active,and essential proteases as targets for inhibitor-based drug design. [Supplemental material is available online at www.genome.org.] Malaria remains one of the most dangerous infectious diseases metalloprotease (falcilysin; Eggleson et al.
    [Show full text]
  • Understanding the Structural Basis of Substrate Recognition By
    www.nature.com/scientificreports OPEN Understanding the structural basis of substrate recognition by Plasmodium falciparum plasmepsin V Received: 02 November 2015 Accepted: 20 July 2016 to aid in the design of potent Published: 17 August 2016 inhibitors Rajiv K. Bedi1,*, Chandan Patel2,*, Vandana Mishra1, Huogen Xiao3, Rickey Y. Yada4 & Prasenjit Bhaumik1 Plasmodium falciparum plasmepsin V (PfPMV) is an essential aspartic protease required for parasite survival, thus, considered as a potential drug target. This study reports the first detailed structural analysis and molecular dynamics simulation of PfPMV as an apoenzyme and its complexes with the substrate PEXEL as well as with the inhibitor saquinavir. The presence of pro-peptide in PfPMV may not structurally hinder the formation of a functionally competent catalytic active site. The structure of PfPMV-PEXEL complex shows that the unique positions of Glu179 and Gln222 are responsible for providing the specificity of PEXEL substrate with arginine at P3 position. The structural analysis also reveals that the S4 binding pocket in PfPMV is occupied by Ile94, Ala98, Phe370 and Tyr472, and therefore, does not allow binding of pepstatin, a potent inhibitor of most pepsin-like aspartic proteases. Among the screened inhibitors, the HIV-1 protease inhibitors and KNI compounds have higher binding affinities for PfPMV with saquinavir having the highest value. The presence of a flexible group at P2 and a bulky hydrophobic group at P3 position of the inhibitor is preferred in the PfPMV substrate binding pocket. Results from the present study will aid in the design of potent inhibitors of PMV. Malaria is an infectious disease that is responsible for causing illness in an estimated 200 to 500 million people and results in an annual mortality of 1 to 2 million persons1.
    [Show full text]
  • Nepenthesin from Monkey Cups for Hydrogen/Deuterium Exchange Mass Spectrometry
    University of Calgary PRISM: University of Calgary's Digital Repository Cumming School of Medicine Cumming School of Medicine Research & Publications 2013-02 Nepenthesin from monkey cups for hydrogen/deuterium exchange mass spectrometry. Rey, Martial; Yang, Menglin; Burns, Kyle M.; Yu, Yaping; Lees-Miller, Susan P.; Schriemer, David C. MOLECULAR & CELLULAR PROTEOMICS Rey, M., Yang, M., Burns, K. M., Yu, Y., Lees-Miller, S. P., & Schriemer, D. C. (2013). Nepenthesin from monkey cups for hydrogen/deuterium exchange mass spectrometry. Molecular and Cellular Proteomics, 12(2), 464-472. doi:10.1074/mcp.M112.025221 http://hdl.handle.net/1880/52223 journal article Downloaded from PRISM: https://prism.ucalgary.ca Research © 2013 by The American Society for Biochemistry and Molecular Biology, Inc. This paper is available on line at http://www.mcponline.org Nepenthesin from Monkey Cups for Hydrogen/ Deuterium Exchange Mass Spectrometry*□S Martial Rey‡, Menglin Yang‡, Kyle M. Burns‡, Yaping Yu‡, Susan P. Lees-Miller‡, and David C. Schriemer‡§ Studies of protein dynamics, structure and interactions fication and characterization, but in the last several years it using hydrogen/deuterium exchange mass spectrometry has also become a powerful tool for interrogating protein (HDX-MS) have sharply increased over the past 5–10 structure and dynamics (1, 2). Solution-phase hydrogen/deu- years. The predominant technology requires fast diges- terium exchange (HDX)1, when coupled with mass spectrom- tion at pH 2–3 to retain deuterium label. Pepsin is used etry (MS), provides rich sets of data that can be mined to almost exclusively, but it provides relatively low efficiency extract structural and dynamic parameters from proteins (3– under the constraints of the experiment, and a selectivity 7).
    [Show full text]
  • WO 2014/122079 A2 14 August 2014 (14.08.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/122079 A2 14 August 2014 (14.08.2014) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07K 1/18 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, PCT/EP2014/05 193 1 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 3 1 January 2014 (3 1.01 .2014) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 13 154063.5 5 February 2013 (05.02.2013) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 13 154797.8 11 February 2013 ( 11.02.2013) EP UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: CHR. HANSEN A S [DK/DK]; Boege A e EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 10-12, DK-2970 Hoersholm (DK).
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • EUROPEAN COMMISSION Brussels, 28 April 2020 REGISTER of FOOD
    EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Food and feed safety, innovation Food processing technologies and novel foods Brussels, 28 April 2020 REGISTER OF FOOD ENZYMES TO BE CONSIDERED FOR INCLUSION IN THE UNION LIST Article 17 of Regulation (EC) No 1332/20081 provides for the establishment of a Register of all food enzymes to be considered for inclusion in the Union list. In accordance with that Article, the Register includes all applications which were submitted within the initial period fixed by that Regulation and which comply with the validity criteria laid down in accordance with Article 9(1) of (EC) No 1331/2008 establishing a common authorisation procedure for food additives, food enzymes and food flavourings2. The Register therefore lists all valid food enzyme applications submitted until 11 March 2015 except those withdrawn by the applicant before that date. Applications submitted after that date are not included in the Register but will be processed in accordance with the Common Authorisation Procedure. The entry of a food enzyme in the Register specifies the identification, the name, the source of the food enzyme as provided by the applicant and the EFSA question number under which the status of the Authority’s assessment can be followed3. As defined by Article 3 of Regulation (EC) No 1332/2008, ‘food enzyme’ subject to an entry in the Register, refers to a product that may contain more than one enzyme capable of catalysing a specific biochemical reaction. In the assessment process, such a food enzyme may be linked with several EFSA question numbers.
    [Show full text]
  • 1 Peptide Therapeutics
    Universal Free E-Book Store Donate Us, In order to keep our Service Alive, We have to pay for placing files (Abstracts, Books, Literature & Software) on File Hosting Servers, Your donations will make our process of payment a bit easier, Please use any one of the Payment Gateway for Donation. Never matter what amount you donate (10’s or 100’s or 1000’s). Universal Free E-Book Store Universal Free E-Book Store PEPTIDE CHEMISTRY AND DRUG DESIGN Universal Free E-Book Store Universal Free E-Book Store PEPTIDE CHEMISTRY AND DRUG DESIGN Edited by BEN M. DUNN Universal Free E-Book Store Copyright © 2015 by John Wiley & Sons, Inc. All rights reserved Published by John Wiley & Sons, Inc., Hoboken, New Jersey Published simultaneously in Canada No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permissions. Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose.
    [Show full text]